MX2022013228A - Composicion farmaceutica que comprende l-triyodotironina (t3) para usarse en el tratamiento de hipoxia tisular y sepsis. - Google Patents

Composicion farmaceutica que comprende l-triyodotironina (t3) para usarse en el tratamiento de hipoxia tisular y sepsis.

Info

Publication number
MX2022013228A
MX2022013228A MX2022013228A MX2022013228A MX2022013228A MX 2022013228 A MX2022013228 A MX 2022013228A MX 2022013228 A MX2022013228 A MX 2022013228A MX 2022013228 A MX2022013228 A MX 2022013228A MX 2022013228 A MX2022013228 A MX 2022013228A
Authority
MX
Mexico
Prior art keywords
triiodothyronine
sepsis
treatment
pharmaceutical composition
heart
Prior art date
Application number
MX2022013228A
Other languages
English (en)
Spanish (es)
Inventor
Constantinos Pantos
Iordanis Mourouzis
Original Assignee
Uni Pharma Kleon Tsetis Pharmaceutical Laboratories S A
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GR20200100200A external-priority patent/GR1010068B/el
Priority claimed from GR20200100695A external-priority patent/GR1010182B/el
Priority claimed from GR20210100216A external-priority patent/GR1010261B/el
Application filed by Uni Pharma Kleon Tsetis Pharmaceutical Laboratories S A filed Critical Uni Pharma Kleon Tsetis Pharmaceutical Laboratories S A
Publication of MX2022013228A publication Critical patent/MX2022013228A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Cardiology (AREA)
  • Molecular Biology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
MX2022013228A 2020-04-21 2021-04-15 Composicion farmaceutica que comprende l-triyodotironina (t3) para usarse en el tratamiento de hipoxia tisular y sepsis. MX2022013228A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GR20200100200A GR1010068B (el) 2020-04-21 2020-04-21 Φαρμακευτικη συνθεση που περιεχει l-τριιωδοθυρονινη (τ3) για χρηση στη θεραπεια ασθενων σε κρισιμη κατασταση με λοιμωξη απο κορωνοϊο
GR20200100695A GR1010182B (el) 2020-11-23 2020-11-23 Φαρμακευτικη συνθεση που περιεχει l-τριιωδοθυρονινη (τ3) για χρηση στην αντιμετωπιση της ιστικης υποξιας
GR20210100216A GR1010261B (el) 2021-03-29 2021-03-29 Φαρμακευτικη συνθεση που περιεχει l-τριιωδοθυρονινη (τ3) για χρηση στην αντιμετωπιση της φλεγμονωδους αντιδρασης και της δυσλειτουργιας του καρδιαγγειακου συστηματος λογω σηψης
PCT/GR2021/000019 WO2021214497A1 (en) 2020-04-21 2021-04-15 Pharmaceutical composition comprising l-triiodothyronine (t3) for use in the treatment of tissue hypoxemia and sepsis

Publications (1)

Publication Number Publication Date
MX2022013228A true MX2022013228A (es) 2022-11-14

Family

ID=76197481

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022013228A MX2022013228A (es) 2020-04-21 2021-04-15 Composicion farmaceutica que comprende l-triyodotironina (t3) para usarse en el tratamiento de hipoxia tisular y sepsis.

Country Status (13)

Country Link
US (1) US12673036B2 (cg-RX-API-DMAC7.html)
EP (1) EP4138810A1 (cg-RX-API-DMAC7.html)
JP (1) JP2023538984A (cg-RX-API-DMAC7.html)
KR (1) KR102991384B1 (cg-RX-API-DMAC7.html)
CN (1) CN115996710B (cg-RX-API-DMAC7.html)
AU (1) AU2021258544A1 (cg-RX-API-DMAC7.html)
BR (1) BR112022021250A2 (cg-RX-API-DMAC7.html)
CA (1) CA3176106A1 (cg-RX-API-DMAC7.html)
GE (2) GEP20247706B (cg-RX-API-DMAC7.html)
IL (1) IL297398B2 (cg-RX-API-DMAC7.html)
MX (1) MX2022013228A (cg-RX-API-DMAC7.html)
WO (1) WO2021214497A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA202212502B (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GEP20247706B (en) 2020-04-21 2024-12-10 Uni Pharma Kleon Tsetis Pharmasceutical Laboratories S A Pharmaceutical composition comprising l-triiodothyronine (t3) for use in the treatment of tissue hypoxemia and sepsis

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5571840A (en) 1993-06-22 1996-11-05 The Regents Of The University Of Michigan Method for treating central nervous system ischemia
WO1995024919A1 (en) * 1994-03-15 1995-09-21 K.U. Leuven Research & Development New use of growth hormone
US20050059574A1 (en) 2000-12-21 2005-03-17 Irwin Klein Compositions of stable T3 and methodes of use thereof
JP2004525874A (ja) 2000-12-21 2004-08-26 リサスサイテック, インコーポレイテッド 安定したt3の組成物およびその使用方法
US8404281B2 (en) 2009-06-08 2013-03-26 Avant Garde Therapeutics & Technologies Llc Formulations
CN103705497B (zh) 2013-12-11 2015-04-01 武汉威立得生物医药有限公司 碘塞罗宁在制备治疗或预防流感病毒感染的药物中的应用
KR102149321B1 (ko) 2015-10-31 2020-08-28 아이오 테라퓨틱스, 인크. Rxr 아고니스트와 갑상선 호르몬의 조합을 사용한 신경계 질환의 치료
EP3908272B1 (en) 2019-01-09 2023-03-22 Uni-Pharma Kleon Tsetis Pharmaceutical Laboratories S.A. L-triiodothyronine (t3) for use in limiting microvascular obstruction
GEP20247706B (en) 2020-04-21 2024-12-10 Uni Pharma Kleon Tsetis Pharmasceutical Laboratories S A Pharmaceutical composition comprising l-triiodothyronine (t3) for use in the treatment of tissue hypoxemia and sepsis
GR1010182B (el) 2020-11-23 2022-03-01 Uni Pharma Κλεων Τσετης Φαρμακευτικα Εργαστηρια Αβεε, Φαρμακευτικη συνθεση που περιεχει l-τριιωδοθυρονινη (τ3) για χρηση στην αντιμετωπιση της ιστικης υποξιας
GR1010068B (el) 2020-04-21 2021-09-01 UNI-PHARMA ΚΛΕΩΝ ΤΣΕΤΗΣ ΦΑΡΜΑΚΕΥΤΙΚΑ ΕΡΓΑΣΤΗΡΙΑ ΑΒΕΕ με δ.τ. "UNI-PHARMA ABEE" Φαρμακευτικη συνθεση που περιεχει l-τριιωδοθυρονινη (τ3) για χρηση στη θεραπεια ασθενων σε κρισιμη κατασταση με λοιμωξη απο κορωνοϊο

Also Published As

Publication number Publication date
KR102991384B1 (ko) 2026-07-14
BR112022021250A2 (pt) 2022-12-06
ZA202212502B (en) 2024-05-30
IL297398B2 (en) 2026-05-01
IL297398B1 (en) 2026-01-01
IL297398A (en) 2022-12-01
KR20230022839A (ko) 2023-02-16
US12673036B2 (en) 2026-07-07
GEP20247706B (en) 2024-12-10
US20230157982A1 (en) 2023-05-25
AU2021258544A1 (en) 2022-10-27
WO2021214497A1 (en) 2021-10-28
CN115996710B (zh) 2024-06-28
EP4138810A1 (en) 2023-03-01
CA3176106A1 (en) 2021-10-28
JP2023538984A (ja) 2023-09-13
GEAP202416094A (en) 2024-07-10
CN115996710A (zh) 2023-04-21

Similar Documents

Publication Publication Date Title
FI3788047T3 (fi) Fgft-estäjän kiinteitä muotoja ja menetelmiä niiden valmistamiseksi
WO2009039980A3 (en) Use of bfgf 1-24 and optionally (arg 8) vasopressin to treat eg s. pneumoniae infection
WO2009043448A3 (en) Neuromedin u-25 and neuromedin s as therapeutic agents
WO2009033756A3 (en) Use of oxyntomodulin alone or in combination with melanotropin potentiating factor as a therapeutic agent
WO2009040036A3 (en) Use of a galanin peptide as a therapeutic agent
WO2009046845A3 (en) Use of a lactoferrin partial peptide peptide as a therapeutic agent
WO2009033661A3 (en) Use of rgdspasskp and optionally angiotensin ii as therapeutic agents in the treatment of eg s. pneumoniae infections
WO2009039973A3 (en) Use of peptide arg-asn-ile-ala-glu-ile-ile-lys-asp-ile-oh or its combination with the peptide asp-arg-gly-asp-ser-oh as a therapeutic agent
WO2009043454A3 (en) Use of pacap-27 as a therapeutic agent
RU2019140862A (ru) Варианты сульфамидазы (sgsh), векторы, композиции и способы, и применения для лечения мукополисахаридоз типа iiia (mps iiia)
WO2009040051A9 (en) Use of the peptide rfmwmk alone or in combination with the peptide ymdgtmsqv as a therapeutic agent
FI3565551T3 (fi) Menetelmiä bakteeri-infektioiden hoitamiseksi vaborbaktaamin ja meropeneemin yhdistelmällä
MX2020007971A (es) Composiciones y metodos para tratar edema pulmonar o inflamacion pulmonar.
ZA202212502B (en) Pharmaceutical composition comprising l-triiodothyronine (t3) for use in the treatment of tissue hypoxia and sepsis
TW200727903A (en) Stable pharmaceutical compositions of 5, 10 methylenetetrahydrofolate
RU2018107930A (ru) Агонисты tlr4, их композиции и применение для лечения рака
WO2025049521A3 (en) Aryl ether analogs as inhibitors of the menin-mll interaction
WO2009039996A3 (en) Use of bradykinin alone or in combination with melanotan ii as a therapeutic agent
EA200600176A1 (ru) Фармацевтические композиции, содержащие аскорбиновую кислоту для лечения грибковых суперинфекций и грибковых рецидивов
WO2021206833A3 (en) Methods and compositions for treating tissue damage resulting from viral infections
WO2009033773A3 (en) Use endothelin 2, alone or combined with a nonapeptide, a peptide as a therapeutic agent
JP2007504194A5 (cg-RX-API-DMAC7.html)
JOP20210221A1 (ar) علاجات مشتركة لاستخدامها في علاج السرطان
RU2010129409A (ru) Способ лечения псороптоза кроликов и отодектоза плотоядных животных
AR129944A1 (es) Uso de compuestos que contienen manganeso para reducir el nivel de ácido úrico en sujetos mamíferos; una composición; un kit y un método de prevención y/o tratamiento